Disease · MONDO_0021113
respiratory failure
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. respiratory failure. Diseases, record MONDO_0021113. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021113
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs50
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NITRIC OXIDE | CHEMBL1200689 | Small molecule | Approval | DailyMed and TTD | 6 | 4 | 4 | Drugs and targets |
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PROPOFOL | CHEMBL526 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AVIPTADIL | CHEMBL1981592 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| COLCHICINE | CHEMBL107 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLONIDINE | CHEMBL134 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 50
See all 50 drugsTargets87
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor alpha | 3 | Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha | 3 | Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha | 3 | Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
1 to 10 of 87
See all 87 targetsTrials56
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04350593 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | Phase 3 | 1,250 | 2022-04-13 | COVID-19 | DAPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
| NCT04356937 | Efficacy of Tocilizumab on Patients With COVID-19 | Phase 3 | 243 | 2021-07-27 | SARS-CoV 2 | TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04311697 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | Phase 2/3 | 203 | 2023-07-24 | Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury | AVIPTADIL | Its record names the disease | ClinicalTrials.gov |
| NCT00578734 | Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old | Phase 2 | 165 | 2012-04-27 | Acute Hypoxemic Respiratory Failure | LUCINACTANT | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT04579393 | Fostamatinib for Hospitalized Adults With COVID-19 | Phase 2 | 59 | 2022-03-02 | Coronavirus Disease 2019 | FOSTAMATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02707523 | Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children | Phase 2 | 48 | 2020-05-27 | Respiratory Syncytial Virus | AZITHROMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT04375397 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | Phase 2 | 46 | 2022-06-01 | CoronaVirus Induced Disease-2019 (COVID-19) | IBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04399980 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Phase 2 | 40 | 2021-05-13 | COVID 19, SARS-CoV 2, Pneumonia | MAVRILIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04388826 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | Phase 2 | 39 | 2021-11-24 | Respiratory Distress Syndrome, Adult | SABIZABULIN | Its record names the disease | ClinicalTrials.gov |
| NCT04335123 | Study of Open Label Losartan in COVID-19 | Phase 1 | 34 | 2024-08-02 | COVID-19 | LOSARTAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 56
See all 56 trialsComparisons in its trials62
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Dapagliflozin 10mg vs Placebo: Improving Clinical Recovery: Hierarchical Composite Outcome Measure Including Death From Any Cause Through Day 30, New/Worsened Organ Dysfunction, Clinical Status at Day 30 and Hospital Discharge Before Day 30 and Alive at Day 30. | 547 of 625 | 532 of 625 | 1,250 | NCT04350593 | Trial comparisons |
| Dapagliflozin 10mg vs Placebo: deaths from any cause | 41 of 625 | 54 of 625 | 1,250 | NCT04350593 | Trial comparisons |
| Dapagliflozin 10mg vs Placebo: serious adverse events | 70 of 613 | 87 of 616 | 1,229 | NCT04350593 | Trial comparisons |
| Tocilizumab vs Placebo: deaths from any cause | 9 of 161 | 4 of 82 | 243 | NCT04356937 | Trial comparisons |
| Tocilizumab vs Placebo: serious adverse events | 19 of 161 | 8 of 82 | 243 | NCT04356937 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: Number of Participants Achieving a Score of 6-8 on NIAID Ordinal Score Through Day 60 | 76 of 131 | 35 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) | 72 of 131 | 33 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: Number of Participants Alive at Day 60 | 85 of 131 | 35 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: deaths from any cause | 46 of 131 | 30 of 65 | 196 | NCT04311697 | Trial comparisons |
| Aviptadil IV in Escalating Doses + Standard of Care vs Placebo + Standard of Care: serious adverse events | 58 of 131 | 32 of 65 | 196 | NCT04311697 | Trial comparisons |
1 to 10 of 62
See all 62 comparisons in its trialsPapers from its trials46
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021113
GET https://conductscience.org/api/diseases/v1/MONDO_0021113/drugs?page=2